bepridil has been researched along with Angina Pectoris in 50 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of bepridil on silent myocardial ischemia and on eicosanoid metabolism, 10 patients with chronic stable angina underwent exercise treadmill testing and 48-hour ambulatory electrocardiographic monitoring both before and after 4 weeks of bepridil administration (150 mg/day)." | 9.07 | Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction. ( Hikita, H; Kanda, Y; Kurita, A; Maruyama, T; Mizuno, K; Nakamura, H; Nishioka, T; Takase, B; Uehata, A, 1994) |
| "The efficacy and safety of bepridil hydrochloride (HCl) and propranolol HCl monotherapy were investigated in a double-blind, parallel-group crossover study in 75 patients with chronic stable angina pectoris." | 9.07 | Comparative efficacy and concomitant use of bepridil and beta blockers in the management of angina pectoris. ( Frishman, WH, 1992) |
| "The calcium antagonist bepridil (bepridil monohydrochloride monohydrate, Org 5730, Cordium) was investigated in comparison with verapamil in a double-blind cross-over design in patients with angina pectoris." | 9.06 | Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial. ( Husted, SE; Krusell, LR; Nielsen, HK; Pluymers, RJ, 1989) |
| "To examine the time-course and potential predictors of prolongation of ventricular repolarization with the calcium antagonist bepridil, the effects of bepridil (300 to 500 mg/day; n = 45) and diltiazem (180 to 300 mg/day; n = 42) on QT and QTc interval duration were analyzed in a randomized double-blind study in patients with angina pectoris." | 9.06 | Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. ( Coudray, P; Funck-Brentano, C; Jaillon, P; Motté, G; Planellas, J, 1990) |
| "The long-term efficacy of bepridil as once-a-day monotherapy was studied in 19 men with stable angina pectoris." | 9.06 | Long-term bepridil monotherapy for angina pectoris. ( Prasad, R; Sharma, MK; Teague, SM; Thadani, U; Voyles, W, 1988) |
| "A total of 178 patients participated in a 14-week, multicenter, double-blind, parallel study to evaluate the comparative efficacy and safety of single daily doses of 200, 300 and 400 mg of bepridil hydrochloride and placebo in the treatment of patients with chronic stable angina pectoris." | 9.05 | Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris. ( DiBianco, R; Shapiro, W; Thadani, U, 1985) |
| "Bepridil, a new calcium-channel blocking agent with an extended plasma elimination half-life of greater than 50 hours, was compared to placebo in 77 patients with confirmed coronary artery disease and chronic stable angina pectoris." | 9.05 | Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients. ( Alpert, J; Chesler, E; Costello, RB; DiBianco, R; Eisenman, MJ; Ferri, DP; Gore, JM; Katz, RJ; Larca, LJ; Spann, J, 1984) |
| "The efficacy of bepridil (400 mg once a day) was assessed in 15 patients with exertional angina pectoris." | 9.05 | Evaluation of bepridil for the treatment of angina pectoris: evidence for preservation of left ventricular function. ( Boucher, CA; Christensen, DM; Kanarek, DJ; Kiess, MC; Zusman, RM, 1985) |
| "Twelve patients with angiographically proven coronary artery disease and stable, exercise-induced angina pectoris were treated in a randomized sequence with placebo (PL) and bepridil tablets in maintenance doses of 200 mg, 400 mg and 600 mg per day for one week each, according to a double blind-protocol with intra-individual cross-over." | 9.05 | [Anti-angina effect of the calcium antagonist bepridil in stable angina pectoris]. ( Bussmann, WD; Kaltenbach, M; Mehlhorn, C; Schneider, W, 1985) |
| "The efficacy of the calcium antagonist bepridil given in a dose of 200-400 mg/day was evaluated in 22 patients with Functional Classes II-III stable angina pectoris." | 7.68 | [Use of bepridil in patients with angina pectoris]. ( Liakishev, AA; Lupanov, VP; Nekrutman, EA; Podinovskaia, IaA, 1991) |
| "Bepridil was well tolerated; most adverse reactions reported were mild and tolerable even at the 400-mg dose." | 6.67 | Comparative efficacy of bepridil versus placebo in angina pectoris: treatment and withdrawal studies. ( Shapiro, W, 1992) |
| " The most frequent adverse effects in both groups were nausea, asthenia, dizziness, headache and diarrhea." | 6.67 | Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group. ( Singh, BN, 1991) |
| "Bepridil is a calcium antagonist with a unique chemical composition and a long elimination half-life (42 hours)." | 6.67 | Bepridil hydrochloride compared with placebo in patients with stable angina pectoris. ( Corday, SR; Hossack, KF; Karliner, JS; Narahara, KA; Singh, BN, 1992) |
| "Bepridil hydrochloride is a unique calcium channel-blocking drug with anti-ischemic and type 1 antiarrhythmic properties." | 6.66 | Comparison of bepridil with nadolol for angina pectoris. ( Humen, DP; Jablonsky, G; Kostuk, WJ; O'Brien, PA; Pflugfelder, PW; Purves, PD, 1987) |
| "The bepridil dosage was adjusted over the 8 weeks of active treatment to an average of 273 mg/day (range 200 to 400)." | 6.66 | Combination propranolol and bepridil therapy in stable angina pectoris. ( Charlap, S; Crawford, MH; DiBianco, R; Farnham, DJ; Frishman, WH; Kostis, JB; Michelson, EL; Michie, DD; Sawin, HS; Zellner, SR, 1985) |
| "Bepridil was reinstituted in these patients with resolution of symptoms and no untoward effects." | 6.66 | Long-term efficacy of bepridil in patients with chronic stable angina pectoris: results of a multicenter, placebo-controlled study of extended bepridil use. ( Alpert, JS; Chesler, E; DiBianco, R; Katz, RJ; Spann, JF, 1985) |
| "Bepridil is a calcium antagonist with direct negative chronotropic, dromotropic, inotropic and vasodilatory actions which reduces myocardial oxygen consumption and increases coronary blood flow, leading to a significant anti-ischaemic and antianginal effect in the absence of reflex tachycardia." | 6.38 | Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. ( Faulds, D; Fitton, A; Hollingshead, LM, 1992) |
| "To investigate the effects of bepridil on silent myocardial ischemia and on eicosanoid metabolism, 10 patients with chronic stable angina underwent exercise treadmill testing and 48-hour ambulatory electrocardiographic monitoring both before and after 4 weeks of bepridil administration (150 mg/day)." | 5.07 | Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction. ( Hikita, H; Kanda, Y; Kurita, A; Maruyama, T; Mizuno, K; Nakamura, H; Nishioka, T; Takase, B; Uehata, A, 1994) |
| "The efficacy and safety of bepridil hydrochloride (HCl) and propranolol HCl monotherapy were investigated in a double-blind, parallel-group crossover study in 75 patients with chronic stable angina pectoris." | 5.07 | Comparative efficacy and concomitant use of bepridil and beta blockers in the management of angina pectoris. ( Frishman, WH, 1992) |
| "To examine the time-course and potential predictors of prolongation of ventricular repolarization with the calcium antagonist bepridil, the effects of bepridil (300 to 500 mg/day; n = 45) and diltiazem (180 to 300 mg/day; n = 42) on QT and QTc interval duration were analyzed in a randomized double-blind study in patients with angina pectoris." | 5.06 | Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. ( Coudray, P; Funck-Brentano, C; Jaillon, P; Motté, G; Planellas, J, 1990) |
| "The calcium antagonist bepridil (bepridil monohydrochloride monohydrate, Org 5730, Cordium) was investigated in comparison with verapamil in a double-blind cross-over design in patients with angina pectoris." | 5.06 | Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial. ( Husted, SE; Krusell, LR; Nielsen, HK; Pluymers, RJ, 1989) |
| "The long-term efficacy of bepridil as once-a-day monotherapy was studied in 19 men with stable angina pectoris." | 5.06 | Long-term bepridil monotherapy for angina pectoris. ( Prasad, R; Sharma, MK; Teague, SM; Thadani, U; Voyles, W, 1988) |
| "Twelve patients with angiographically proven coronary artery disease and stable, exercise-induced angina pectoris were treated in a randomized sequence with placebo (PL) and bepridil tablets in maintenance doses of 200 mg, 400 mg and 600 mg per day for one week each, according to a double blind-protocol with intra-individual cross-over." | 5.05 | [Anti-angina effect of the calcium antagonist bepridil in stable angina pectoris]. ( Bussmann, WD; Kaltenbach, M; Mehlhorn, C; Schneider, W, 1985) |
| "The efficacy of bepridil (400 mg once a day) was assessed in 15 patients with exertional angina pectoris." | 5.05 | Evaluation of bepridil for the treatment of angina pectoris: evidence for preservation of left ventricular function. ( Boucher, CA; Christensen, DM; Kanarek, DJ; Kiess, MC; Zusman, RM, 1985) |
| "A total of 178 patients participated in a 14-week, multicenter, double-blind, parallel study to evaluate the comparative efficacy and safety of single daily doses of 200, 300 and 400 mg of bepridil hydrochloride and placebo in the treatment of patients with chronic stable angina pectoris." | 5.05 | Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris. ( DiBianco, R; Shapiro, W; Thadani, U, 1985) |
| "Bepridil, a new calcium-channel blocking agent with an extended plasma elimination half-life of greater than 50 hours, was compared to placebo in 77 patients with confirmed coronary artery disease and chronic stable angina pectoris." | 5.05 | Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients. ( Alpert, J; Chesler, E; Costello, RB; DiBianco, R; Eisenman, MJ; Ferri, DP; Gore, JM; Katz, RJ; Larca, LJ; Spann, J, 1984) |
| " The purpose of these studies was to compare the effects of bepridil versus those of propranolol or diltiazem in patients with exertional angina pectoris." | 3.68 | Effects of antianginal therapy on left ventricular systolic and diastolic performance: comparison of the response to bepridil, propranolol, and diltiazem. ( Boucher, CA; Christensen, DM; Higgins, J; Zusman, RM, 1992) |
| "The efficacy of the calcium antagonist bepridil given in a dose of 200-400 mg/day was evaluated in 22 patients with Functional Classes II-III stable angina pectoris." | 3.68 | [Use of bepridil in patients with angina pectoris]. ( Liakishev, AA; Lupanov, VP; Nekrutman, EA; Podinovskaia, IaA, 1991) |
| "Bepridil is a calcium antagonist with a unique chemical composition and a long elimination half-life (42 hours)." | 2.67 | Bepridil hydrochloride compared with placebo in patients with stable angina pectoris. ( Corday, SR; Hossack, KF; Karliner, JS; Narahara, KA; Singh, BN, 1992) |
| " The most frequent adverse effects in both groups were nausea, asthenia, dizziness, headache and diarrhea." | 2.67 | Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group. ( Singh, BN, 1991) |
| "Bepridil was well tolerated; most adverse reactions reported were mild and tolerable even at the 400-mg dose." | 2.67 | Comparative efficacy of bepridil versus placebo in angina pectoris: treatment and withdrawal studies. ( Shapiro, W, 1992) |
| "Bepridil hydrochloride is a unique calcium channel-blocking drug with anti-ischemic and type 1 antiarrhythmic properties." | 2.66 | Comparison of bepridil with nadolol for angina pectoris. ( Humen, DP; Jablonsky, G; Kostuk, WJ; O'Brien, PA; Pflugfelder, PW; Purves, PD, 1987) |
| "The bepridil dosage was adjusted over the 8 weeks of active treatment to an average of 273 mg/day (range 200 to 400)." | 2.66 | Combination propranolol and bepridil therapy in stable angina pectoris. ( Charlap, S; Crawford, MH; DiBianco, R; Farnham, DJ; Frishman, WH; Kostis, JB; Michelson, EL; Michie, DD; Sawin, HS; Zellner, SR, 1985) |
| "Bepridil was reinstituted in these patients with resolution of symptoms and no untoward effects." | 2.66 | Long-term efficacy of bepridil in patients with chronic stable angina pectoris: results of a multicenter, placebo-controlled study of extended bepridil use. ( Alpert, JS; Chesler, E; DiBianco, R; Katz, RJ; Spann, JF, 1985) |
| "Bepridil is a calcium antagonist with direct negative chronotropic, dromotropic, inotropic and vasodilatory actions which reduces myocardial oxygen consumption and increases coronary blood flow, leading to a significant anti-ischaemic and antianginal effect in the absence of reflex tachycardia." | 2.38 | Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. ( Faulds, D; Fitton, A; Hollingshead, LM, 1992) |
| "Bepridil is a unique calcium antagonist with a broad pharmacologic profile and demonstrated efficacy as an antianginal agent." | 2.38 | Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. ( Singh, BN, 1992) |
| "Bepridil is an anti-anginal agent with a novel chemical structure." | 2.37 | Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. ( Alpert, JS; Coumel, P; Greeff, K; Krikler, DM; Remme, WJ; Schönbaum, E; Verduyn, CW, 1985) |
| "Bepridil is an investigational calcium channel blocking agent with antianginal activity that has a distinct and complex pharmacologic profile." | 2.37 | Bepridil: a new long-acting calcium channel blocking agent. ( Spinler, SA; Zeller, FP, 1987) |
| "Treatment with bepridil (10-20 microM) for 30 min increased the production of reactive oxygen intermediates (ROI) by more than 50%." | 1.31 | Effect of the antianginal drug bepridil on intracellular Ca2+ release and extracellular Ca2+ influx in human neutrophils. ( Chen, LW; Jan, CR, 2001) |
| " The 9-year French experience suggests that bepridil is a safe and effective agent for treatment of angina pectoris in properly selected patients." | 1.28 | Safety of bepridil: from review of the European data. ( Coumel, P, 1992) |
| "Bepridil was found to decrease left ventricular work, by 14." | 1.26 | Bepridil-induced modifications of cardiac performance in the anesthetized dog: comparison with nitroglycerin and propranolol. ( Beaughard, M; Labrid, C; Lamar, JC; Piris, P, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (60.00) | 18.7374 |
| 1990's | 18 (36.00) | 18.2507 |
| 2000's | 2 (4.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zelesko, MJ | 1 |
| McComsey, DF | 1 |
| Hageman, WE | 1 |
| Nortey, SO | 1 |
| Baker, CA | 1 |
| Maryanoff, BE | 1 |
| Kane, KA | 1 |
| Winslow, E | 1 |
| DiBianco, R | 5 |
| Alpert, J | 1 |
| Katz, RJ | 2 |
| Spann, J | 1 |
| Chesler, E | 2 |
| Ferri, DP | 1 |
| Larca, LJ | 1 |
| Costello, RB | 1 |
| Gore, JM | 2 |
| Eisenman, MJ | 1 |
| Hill, JA | 3 |
| O'Brien, JT | 2 |
| Scott, E | 1 |
| Conti, CR | 1 |
| Pepine, CJ | 2 |
| Narahara, KA | 3 |
| Shapiro, W | 4 |
| Weliky, I | 2 |
| Park, J | 2 |
| Flammang, D | 1 |
| Waynberger, M | 1 |
| Jansen, FH | 1 |
| Paillet, R | 1 |
| Coumel, P | 3 |
| Labrid, C | 1 |
| Piris, P | 1 |
| Lamar, JC | 1 |
| Beaughard, M | 1 |
| Zusman, RM | 4 |
| Higgins, J | 2 |
| Christensen, D | 2 |
| Boucher, CA | 4 |
| Takase, B | 1 |
| Kurita, A | 1 |
| Hikita, H | 1 |
| Uehata, A | 1 |
| Nishioka, T | 1 |
| Maruyama, T | 1 |
| Mizuno, K | 1 |
| Nakamura, H | 1 |
| Kanda, Y | 1 |
| Wijnand, HP | 1 |
| Weiss, RJ | 1 |
| Jan, CR | 2 |
| Tseng, CJ | 1 |
| Chen, LW | 1 |
| Hollingshead, LM | 1 |
| Faulds, D | 1 |
| Fitton, A | 1 |
| Singh, BN | 3 |
| Gorlin, R | 1 |
| Christensen, DM | 2 |
| De Marco, T | 1 |
| Deedwania, P | 1 |
| Chatterjee, K | 1 |
| Karliner, JS | 1 |
| Corday, SR | 1 |
| Hossack, KF | 1 |
| Frishman, WH | 2 |
| Nekrutman, EA | 1 |
| Lupanov, VP | 1 |
| Liakishev, AA | 1 |
| Podinovskaia, IaA | 1 |
| Funck-Brentano, C | 1 |
| Coudray, P | 1 |
| Planellas, J | 1 |
| Motté, G | 1 |
| Jaillon, P | 1 |
| Alpert, JS | 3 |
| Greeff, K | 1 |
| Krikler, DM | 1 |
| Remme, WJ | 2 |
| Schönbaum, E | 1 |
| Verduyn, CW | 1 |
| Massingham, R | 1 |
| Van Zwieten, PA | 1 |
| Nielsen, HK | 1 |
| Krusell, LR | 1 |
| Husted, SE | 1 |
| Pluymers, RJ | 1 |
| Destors, JM | 1 |
| Boissel, JP | 1 |
| Philippon, AM | 1 |
| Schbath, J | 1 |
| Gibelin, P | 1 |
| Lloret, JL | 1 |
| Morand, P | 1 |
| Matteoli, S | 1 |
| Trappolini, M | 1 |
| Galli, V | 1 |
| Federici, AR | 1 |
| Borgia, MC | 1 |
| Greco, V | 1 |
| Sharma, MK | 1 |
| Voyles, W | 1 |
| Prasad, R | 1 |
| Teague, SM | 1 |
| Thadani, U | 2 |
| Pflugfelder, PW | 1 |
| Humen, DP | 1 |
| O'Brien, PA | 1 |
| Purves, PD | 1 |
| Jablonsky, G | 1 |
| Kostuk, WJ | 1 |
| Zeller, FP | 1 |
| Spinler, SA | 1 |
| Manouvrier, J | 1 |
| Sagot, M | 1 |
| Caron, C | 1 |
| Vaskmann, G | 1 |
| Leroy, R | 1 |
| Reade, R | 1 |
| Ducloux, G | 1 |
| van Hoogenhuyze, DC | 1 |
| Krauss, XH | 1 |
| Hofman, A | 1 |
| Storm, CJ | 1 |
| Kruyssen, HA | 1 |
| Parker, JO | 1 |
| Farrell, B | 1 |
| Vetrovec, G | 1 |
| Borer, JS | 1 |
| Friedman, C | 1 |
| Charlap, S | 1 |
| Farnham, DJ | 1 |
| Sawin, HS | 1 |
| Michelson, EL | 1 |
| Crawford, MH | 1 |
| Kostis, JB | 1 |
| Zellner, SR | 1 |
| Michie, DD | 1 |
| Rae, AP | 1 |
| Beattie, JM | 1 |
| Lawrie, TD | 1 |
| Hutton, I | 1 |
| Schneider, W | 1 |
| Mehlhorn, C | 1 |
| Kaltenbach, M | 1 |
| Bussmann, WD | 1 |
| Lai, C | 1 |
| Pirisi, R | 1 |
| Onnis, E | 1 |
| Tallu, B | 1 |
| Delogu, G | 1 |
| Cherchi, A | 2 |
| Arca, M | 1 |
| Kanarek, DJ | 1 |
| Kiess, MC | 1 |
| Spann, JF | 1 |
6 reviews available for bepridil and Angina Pectoris
| Article | Year |
|---|---|
Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.
Topics: Angina Pectoris; Animals; Bepridil; Biological Availability; Drug Interactions; Electrophysiology; H | 1992 |
Bepridil treatment of chronic stable angina: a review of comparative studies versus placebo, nifedipine, and diltiazem.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Chronic Disease; Diltiazem; Female; Humans; Male; Meta-Analy | 1992 |
Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Arrhythmias, Cardiac; Bepridil; Chronic Disease; El | 1992 |
Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Bepridil; Calcium; Electrocardiography; Hemodynamics | 1985 |
Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.
Topics: Angina Pectoris; Animals; Bepridil; Coronary Disease; Humans | 1989 |
Bepridil: a new long-acting calcium channel blocking agent.
Topics: Angina Pectoris; Bepridil; Calcium Channel Blockers; Humans; Pyrrolidines | 1987 |
26 trials available for bepridil and Angina Pectoris
| Article | Year |
|---|---|
Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients.
Topics: Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; | 1984 |
Effects of bepridil on exercise tolerance in chronic stable angina: a double-blind, randomized, placebo-controlled, crossover trial.
Topics: Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical | 1984 |
Effects of bepridil on the resting electrocardiogram.
Topics: Aged; Angina Pectoris; Anti-Arrhythmia Agents; Bepridil; Clinical Trials as Topic; Coronary Disease; | 1984 |
Evaluation of bepridil, a new antianginal agent: clinical and hemodynamic alterations during the treatment of stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Hemodyna | 1984 |
Bepridil improves left ventricular performance in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Blood Pressure; Cardiac Output; Exercise Test; Female; Human | 1993 |
Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Angina Pectoris; Arachidonic Acids; Bepridil; Chronic Dis | 1994 |
Bepridil hydrochloride compared with placebo in patients with stable angina pectoris.
Topics: Analysis of Variance; Angina Pectoris; Bepridil; Double-Blind Method; Electrocardiography; Exercise | 1992 |
Comparative efficacy of bepridil versus placebo in angina pectoris: treatment and withdrawal studies.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Bepridil; Electrocardiography; Female; Humans; Male | 1992 |
Comparative efficacy and concomitant use of bepridil and beta blockers in the management of angina pectoris.
Topics: Aged; Angina Pectoris; Bepridil; Double-Blind Method; Drug Therapy, Combination; Electrocardiography | 1992 |
Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Chronic Disease; Diltiazem; Double-Blind Method; Drug Tolera | 1991 |
Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris.
Topics: Angina Pectoris; Bepridil; Diltiazem; Electrocardiography; Electrophysiology; Female; Humans; Male; | 1990 |
Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials | 1989 |
Controlled clinical trial of bepridil, propranolol and placebo in the treatment of exercise induced angina pectoris. B.I.S. Research Group.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Double-Blind Method; Electrocardiography; Exercise; Female; | 1989 |
[Bepridil in stable angina of effort: a double-blind comparison with verapamil].
Topics: Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; | 1988 |
Long-term bepridil monotherapy for angina pectoris.
Topics: Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical | 1988 |
Comparison of bepridil with nadolol for angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Angiography; Bepridil; Clinical Trials as Topic; Drug Administration S | 1987 |
Comparative antianginal effects of bepridil and propranolol in angina pectoris.
Topics: Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; | 1986 |
Effect of bepridil in patients with chronic stable angina: results of a multicenter trial.
Topics: Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Doubl | 1985 |
Combination propranolol and bepridil therapy in stable angina pectoris.
Topics: Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Doubl | 1985 |
Hemodynamic actions of bepridil during treatment of stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as | 1985 |
Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina.
Topics: Adult; Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind M | 1985 |
[Anti-angina effect of the calcium antagonist bepridil in stable angina pectoris].
Topics: Adult; Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as | 1985 |
[Evaluation of clinical efficacy and tolerance of bepridil in patients with effort-induced angina pectoris].
Topics: Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; | 1985 |
Evaluation of bepridil for the treatment of angina pectoris: evidence for preservation of left ventricular function.
Topics: Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Doubl | 1985 |
Long-term efficacy of bepridil in patients with chronic stable angina pectoris: results of a multicenter, placebo-controlled study of extended bepridil use.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Double-B | 1985 |
Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Clinical Trials as | 1985 |
18 other studies available for bepridil and Angina Pectoris
| Article | Year |
|---|---|
Cardiac-slowing amidines containing the 3-thioindone group. Potential antianginal agents.
Topics: Amidines; Aminophylline; Angina Pectoris; Animals; Benzilates; Biological Assay; Dogs; Glucagon; Hea | 1983 |
Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil.
Topics: Aconitine; Action Potentials; Anesthesia; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythm | 1980 |
Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Bepridil; Calcium Channel Blockers; Electrocardi | 1983 |
Bepridil-induced modifications of cardiac performance in the anesthetized dog: comparison with nitroglycerin and propranolol.
Topics: Anesthesia; Angina Pectoris; Animals; Bepridil; Blood Pressure; Cardiac Output; Dogs; Female; Heart | 1982 |
Bioequivalence revisited: non-parametric analysis of two-period cross-over studies.
Topics: Algorithms; Analysis of Variance; Angina Pectoris; Bepridil; Computer Simulation; Confidence Interva | 1993 |
Bepridil and agranulocytosis.
Topics: Aged; Agranulocytosis; Angina Pectoris; Bepridil; Chronic Disease; Female; Humans; Male | 1993 |
A novel action of the antianginal drug bepredil: induction of internal Ca(2+) release and external Ca(2+) influx in Madin-Darby canine kidney (MDCK) epithelial cells.
Topics: Angina Pectoris; Animals; Bepridil; Biological Transport; Calcium; Calcium Channel Blockers; Cells, | 2000 |
Effect of the antianginal drug bepridil on intracellular Ca2+ release and extracellular Ca2+ influx in human neutrophils.
Topics: Angina Pectoris; Bepridil; Calcium; Calcium Channel Blockers; Calcium Signaling; Estrenes; Humans; I | 2001 |
Management of angina pectoris: the evolution of therapy--are there still unresolved needs?
Topics: Angina Pectoris; Bepridil; Calcium Channel Blockers; Humans; Ventricular Function, Left | 1992 |
Effects of antianginal therapy on left ventricular systolic and diastolic performance: comparison of the response to bepridil, propranolol, and diltiazem.
Topics: Angina Pectoris; Bepridil; Diastole; Diltiazem; Exercise Test; Humans; Propranolol; Systole; Vascula | 1992 |
Systemic and coronary hemodynamic effects of bepridil in patients with depressed left ventricular function.
Topics: Aged; Angina Pectoris; Bepridil; Coronary Circulation; Epinephrine; Hemodynamics; Humans; Male; Midd | 1992 |
Safety of bepridil: from review of the European data.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Bepridil; Clinical Trials as Topic; Female; France; Humans | 1992 |
[Use of bepridil in patients with angina pectoris].
Topics: Adult; Angina Pectoris; Bepridil; Exercise; Female; Humans; Male; Middle Aged | 1991 |
Bepridil for angina pectoris.
Topics: Angina Pectoris; Bepridil; Chronic Disease; Clinical Trials as Topic; Humans | 1991 |
Bepridil.
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Bepridil; Humans; Middle Aged; Pyrrolidines | 1988 |
[Unstable angina treated with bepridil. Temporary regression of the electric signs of impregnation].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Bepridil; Calcium Channel Blockers; Fema | 1986 |
Nine cases of torsade de pointes with bepridil administration.
Topics: Aged; Angina Pectoris; Bepridil; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Ele | 1986 |
Dose related coronary and systemic haemodynamic effects of intravenous bepridil in patients with coronary artery disease.
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Bepridil; Coronary Circulation; Coronary Disease; Do | 1987 |